Search results for " Drug"

showing 10 items of 3138 documents

Bloodstream infections in intensive care unit patients: Distribution and antibiotic resistance of bacteria

2015

Vincenzo Russotto,1 Andrea Cortegiani,1 Giorgio Graziano,2 Laura Saporito,2 Santi Maurizio Raineri,1 Caterina Mammina,2 Antonino Giarratano1 1Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, Paolo Giaccone University Hospital, University of Palermo, Palermo, Italy; 2Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo, Palermo, Italy Abstract: Bloodstream infections (BSIs) are among the leading infections in critically ill patients. The case-fatality rate associated with BSIs in patients admitted to intensive care units (ICUs) reaches 35%–50%. The emergence and diffusi…

medicine.medical_specialtybloodstream infectionsmedicine.drug_classAntibioticsICU; MDR; antibiotic; bloodstream infections; intensive care unit; multidrug resistantSettore MED/41 - AnestesiologiaReviewBloodstream infectionmedicine.disease_causelcsh:Infectious and parasitic diseaseslaw.inventionAntibiotic resistancelawIntensive careEpidemiologyMDRmedicinelcsh:RC109-216Pharmacology (medical)Intensive care unitMED/41 - ANESTESIOLOGIAIntensive care medicinePharmacologybiologybusiness.industryAntibioticAcinetobacterbiology.organism_classificationIntensive care unitMultiple drug resistanceInfectious DiseasesMultidrug resistantStaphylococcus aureusICUAntibiotic; Bloodstream infections; ICU; Intensive care unit; MDR; Multidrug resistantbusiness
researchProduct

Appropriate cytotoxic drugs usages in solid tumors: Impact of appropriate use referentials

2012

Summary Background The appropriate use of anticancer drugs is at major stake of steering health facilities. French health authorities have specifically elaborated evidence-based principles and guidelines on good practice for the management of anticancer drugs called “referentiels de bon usage” (RBU in French). Objectives The primary aim of the survey is to confront therapeutic practices and PGU. The secondary objective is to evaluate the impact of PGU on “outside the prescribing guidelines” therapeutic use, as compared with a similar study conducted in 2004. Patients and methods The survey was conducted from 1st July 2008 to 31st March 2009 at two reference centers in cancer research, and i…

medicine.medical_specialtybusiness.industryAlternative medicineEvidence-based medicineDiseaseAppropriate useAnticancer drugScientific evidencemedicinePharmacology (medical)Prospective payment systemIntensive care medicineGood practicebusinessLe Pharmacien Hospitalier et Clinicien
researchProduct

Role of multidrug-resistant pathogens in health-care-associated pneumonia

2011

Comment on: Rethinking the concepts of community-acquired and health-care-associated pneumonia. [Lancet Infect Dis. 2010]

medicine.medical_specialtybusiness.industryHealth-care-associated pneumoniamedicine.diseaseHealth care associatedSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheNOMultidrug-resistant pathogensMultiple drug resistancePneumoniaInfectious Diseasesmedicinepneumonia multidrug-resistant pathogensHealth-care-associated pneumonia; Multidrug-resistant pathogensIntensive care medicinebusiness
researchProduct

Cutaneous Adverse Reactions to Highly Antiretroviral Therapy in HIV-Positive Patients

2013

Adverse drug reactions to highly antiretroviral therapy (HAART) are major obstacles in its success. Although overall mortality from HIV has dramatically declined owing to HAART, these antiretroviral regimens have been associated with a wide spectrum of severe cutaneous reactions. The severity of cutaneous adverse reactions varies greatly, and some may be difficult to manage. To optimize adherence and efficacy of antiretroviral treatment, clinicians must focus on preventing adverse effects whenever possible, and distinguish those that are self-limited from those that are potentially serious. This paper presents the case of a serious cutaneous adverse reaction to Atripla in a HIV-positive 50-…

medicine.medical_specialtybusiness.industryHuman immunodeficiency virus (HIV)Adverse drug reactionAdverse drug reactionsHIVDermatologylcsh:RL1-803medicine.disease_causeAntiretroviral therapyPublished online: May 2014Surgerylcsh:DermatologymedicineAntiretroviral treatmentSettore MED/35 - Malattie Cutanee E VenereeDrug reactionIntensive care medicinebusinessAdverse effectHighly antiretroviral therapySkin
researchProduct

Clinical research focused in European adult women with minority diseases: Do we try hard enough?

2021

We analyzed the European countries participation in clinical trials addressing to new drug development focused on rare diseases in women comparing to more prevalent diseases as breast cancer. Participation was not associated with type of healthcare system neither socio-economic features, but it was associated with population size. Protocol ratios focused on breast cancer vs. orphan drugs and rare diseases was 15:1 and 9:1, respectively, mainly focused on ovarian cancer. Protocol number was insufficient to evaluate the success of Regulation (EC) 141/2000, it is necessary to increase the scientific quality and the number of really new molecules.

medicine.medical_specialtybusiness.industryMEDLINEmedicine.diseaseAdult womenClinical trialOrphan drugClinical researchBreast cancerDrug developmentFamily medicineGeneral Health ProfessionsMedicinebusinessOvarian cancer
researchProduct

A study of hurdles in mass treatment of schistosomiasis in KwaZulu-Natal, South Africa

2015

Background: It has been estimated that 700 million people worldwide and 5.2 million people in South Africa are in need of annual treatment for schistosomiasis. In accordance with the current policy the Department of Health (DoH) in KwaZulu-Natal province, South Africa, aimed to reach 75% treatment coverage in a mass treatment campaign (MTC) of schools in a schistosomiasis-endemic area.Methods: A cross-sectional study was designed to explore the implementation, coverage, challenges and limitations of a DoH MTC in a middle-income country. The study was conducted by exploring nurses’ and research team records, school enrolment lists and parental consent forms.Results: Slightly more than 10 000…

medicine.medical_specialtybusiness.industryRural healtheducationPublic Health Environmental and Occupational HealthAlternative medicineSchistosomiasismedicine.diseaseSurgeryFamily medicinemedicineMass treatmentHealth educationParental consentFamily PracticebusinessMass drug administrationKwazulu natalSouth African Family Practice
researchProduct

Effect of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization in women with acute heart failure

2020

Abstract Background Guidelines recommend evaluating the risk/benefit ratio of novel therapies individually in women and men, as the pathophysiology and the response to treatment may differ between women and men. Among patients with acute heart failure (AHF), a strategy of intensive vasodilation, compared with usual care, overall did provide comparable outcomes. Purpose To evaluate the effect of a strategy that emphasized early intensive and sustained vasodilation in women with AHF. Methods In a randomized, open-label blinded-end-point trial patients hospitalized for AHF were enrolled in 10 hospitals in Switzerland, Bulgaria, Germany, Brazil, and Spain. Inclusion criteria were AHF expressed …

medicine.medical_specialtybusiness.industryVasodilationmedicine.diseasePatient roomPharmacotherapyBlood pressurePlasma drug concentrationInternal medicineHeart failureUsual caremedicineCardiologyCardiology and Cardiovascular MedicineAdverse effectbusinessEuropean Heart Journal
researchProduct

Statins stimulate the production of a soluble form of the receptor for advanced glycation end products

2013

The beneficial effects of statin therapy in the reduction of cardiovascular pathogenesis, atherosclerosis, and diabetic complications are well known. The receptor for advanced glycation end products (RAGE) plays an important role in the progression of these diseases. In contrast, soluble forms of RAGE act as decoys for RAGE ligands and may prevent the development of RAGE-mediated disorders. Soluble forms of RAGE are either produced by alternative splicing [endogenous secretory RAGE (esRAGE)] or by proteolytic shedding mediated by metalloproteinases [shed RAGE (sRAGE)]. Therefore we analyzed whether statins influence the production of soluble RAGE. Lovastatin treatment of either mouse alveol…

medicine.medical_specialtyendocrine system diseasesADAM10Receptor for Advanced Glycation End ProductsBeta-CyclodextrinsQD415-436PharmacologyBiochemistryCell LineRAGE (receptor)MiceEndocrinologyGlycationInternal medicinediabetic complicationsmedicineAnimalsHumansSecretionLovastatincardiovascular diseasesReceptors ImmunologicReceptorResearch ArticlesDose-Response Relationship DrughypercholesterolemiaChemistrybeta-CyclodextrinsHEK 293 cellsTricarboxylic Acidsnutritional and metabolic diseasesCell BiologyBridged Bicyclo Compounds HeterocyclicADAM 10CholesterolFarnesyl-Diphosphate FarnesyltransferaseEndocrinologySolubilitycardiovascular systemLovastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsatherosclerosishuman activitiesmedicine.drugJournal of Lipid Research
researchProduct

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

2015

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analysing the nephroprotective effect of antihyperglycaemic drugs beyond their glucose lowering effect and improved glycaemic control on the prevention and progression of diabetic nephropathy. This article analyzes the exisiting data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs, apart from their well known blood gluc…

medicine.medical_specialtylcsh:MedicineReviewPharmacologyalbuminuriaDiabetic nephropathyDDP4 inhibitorsDiabetes mellitusantihyperglycemic drugsSGLT2 inhibitionRenin–angiotensin systemDiabetic nephropathiesmedicineIntensive care medicineGlycemicnephroprotectionKidneyDiabetisdiabetic chronic kidney diseasebusiness.industrydiabetic nephropathylcsh:RDiabetesGeneral MedicineNefropaties diabètiquesmedicine.diseaseBlockadeClinical trialmedicine.anatomical_structurediabetes mellitusAlbuminuriaglucagon-like peptide agonistsmedicine.symptombusiness
researchProduct

Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug us…

2011

Abstract The global spread of hepatitis B virus (HBV) and hepatitis C virus (HCV), their high chronicity rates and their progression to cirrhosis and hepatocellular carcinoma, are major public health problems. Research and intervention programmes for special population groups are needed in order to assess their infection risk and set up suitable prevention and control strategies. Aim of this paper is to give health care professionals information on HBV and HCV infections amongst migrants, drug users and prison inmates. The manuscript is an official Position Paper on behalf of the following Scientific Societies: Italian Association for the Study of the Liver (A.I.S.F.), Italian Society of In…

medicine.medical_specialtymedia_common.quotation_subjectHCV HBV vaccimantion inmatesPopulationPsychological interventionPrisonContext (language use)migrantsmedicine.disease_causeVulnerable PopulationsDrug UsersHepatitis B ChronicHealth carehcvMedicineHumanseducationPsychiatrySubstance Abuse Intravenousmedia_commonHepatitis B virusTransients and Migrantseducation.field_of_studyHepatologybusiness.industryPublic healthPrisonersVaccinationGastroenterologyvirus diseasesHepatitis C Chronicintravenous drug usersSocioeconomic FactorsPractice Guidelines as TopichbvPosition paperhbv; hcv; intravenous drug users; migrants; prison inmatesbusinessprison inmates
researchProduct